Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970–1979 1974: FDA approves doxorubicin.

Similar presentations


Presentation on theme: "Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970–1979 1974: FDA approves doxorubicin."— Presentation transcript:

1 Progress Against Leukemia

2 1970–1979

3 Progress Against Leukemia 1970– : FDA approves doxorubicin

4 Progress Against Leukemia 1970– : Era of bone marrow transplantation begins – extending lives of many patients with leukemia and lymphoma

5 Progress Against Leukemia 1970– : Chlorambucil induces remissions for chronic lymphocytic leukemia

6 Progress Against Leukemia 1980–1989

7 Progress Against Leukemia 1980– : Daunorubicin proven superior to doxorubicin for AML

8 Progress Against Leukemia 1980– : National bone marrow transplantation registry is established

9 Progress Against Leukemia 1980–1989 Late 1980s: Benzene established to cause cancer

10 Progress Against Leukemia 1990–1999

11 Progress Against Leukemia 1990– : Lymphocyte transfusions re-induce leukemia remissions 1995: Approval of tretinoin leads to 95 percent cure rate for rare leukemia

12 Progress Against Leukemia 2000–Present

13 Progress Against Leukemia 2000–Present 2000: Fludarabine works faster, better for patients with CLL

14 Progress Against Leukemia 2000–Present 2001: New targeted therapy – imatinib – proven effective against chronic myelogenous leukemia

15 Progress Against Leukemia 2000–Present 2004, 2006: Epigenetic drugs approved to prevent cancer in patients with myelodysplastic syndromes

16 Progress Against Leukemia 2000–Present 2005: Drug approved to reduce oral sores caused by cancer treatment

17 Progress Against Leukemia 2000–Present 2006: New drug helps CML patients who become resistant to imatinib

18 Progress Against Leukemia 2000–Present 2007: Addition of an arsenic compound found to improve survival for rare form of leukemia 2007: Study supports expanded use of dasatinib for CML 2007: Bendamustine is effective against chronic lymphocytic leukemia (CLL)

19 Progress Against Leukemia 2000–Present 2009: Genome of acute myelogenous leukemia is sequenced

20 Progress Against Leukemia 2000–Present 2010: Tyrosine kinase inhibitors provide additional options for CML 2011: Adding rituximab extends survival for chronic lymphocytic leukemia

21 Progress Against Leukemia Five-Year Survival Source: National Cancer Institute

22 Progress Against Leukemia Mortality Source: National Cancer Institute

23 Progress Against Leukemia New Cases Source: National Cancer Institute

24 Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures


Download ppt "Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970–1979 1974: FDA approves doxorubicin."

Similar presentations


Ads by Google